Platelet, Plasma Market – Analysis and Forecast (2019-2026) – by Component, by Distribution Channel, by Applications, by Geography

Platelet, Plasma Market – Analysis and Forecast (2019-2026) – by Component, by Distribution Channel, by Applications, by Geography

Market Scenario

Platelet, Plasma Market is estimated to surpass $ 6.3 Billion markets in 2018 and reach USD XX  Billion by 2026, at a Compound Annual Growth Rate (CAGR) of XX % during the forecast period 2018-2026 globally.Platelet, Plasma Market By ComponentA rising incidence of haemophilia, thrombocytopenia, autoimmune diseases as well as other infectious and rare disease will serve to be a key driver for the platelet and plasma market growth. According to the American Academy of Neurology, plasma can be used for the treatment of various neurological conditions. Plasma exchange process involves replacing plasma in a person’s blood. This process can be used for the treatment of conditions such as inflammatory dis-immune neuropathies, multiple sclerosis, myasthenia gravis, and other disorders will accelerate industry growth during the forecast period Increasing blood transfusion rates in Europe will drive the Platelet, Plasma Market growth over the forecast period. Blood transfusion process is primarily done to isolate the desired blood components such as red blood cells, plasma, platelets and other vital components of the blood. Government initiatives to create awareness regarding source plasma collection, as well as the use of lifesaving plasma protein therapies in rare diseases, will positively impact the market growth. Advancements in healthcare infrastructure coupled with the increasing number of blood transfusions will directly impact the growth of Platelet, Plasma Market in the coming years. The advent of technologically advanced platelet and plasma products is another major driver that will augment the market growth. Use of platelets and plasma in the treatment of rare, debilitating, life-threatening conditions and chronic diseases such as Hepatitis B heavily influences the growth of the market. Plasma-derived from blood can be used in treating rare diseases wherein no other alternative treatment is available. For instance, use of plasma for treatment of Ebola virus during its outbreak in West Africa. Factors will augment the market growth during the forecast period. Platelet segment accounted for the largest market share and will continue to dominate the industry over the forecast period. The reason can be attributed to the increasing adoption of advanced technologies for the treatment of various diseases. Platelets are used in various surgical procedures due to its vivid therapeutic and prophylactic applications. According to the World Federation of Haemophilia (WFH), in 2016, around 2,95,866 people suffered from bleeding disorders wherein 1,84,723 accounted for hemophilia. The increasing demand of platelets for treatment of hemophilia and other blood disorders will fuel the segment growth over the forecast period. Moreover, various initiatives by the government and other organizations to encourage blood donation among people and the adoption of advanced technologies in developed and developing economies will further boost the industry growth. North America Platelet, Plasma Market accounted for the highest revenue in 2017 and is projected to grow at a significant rate during the forecast period. The growth is attributed to the increasing cases of cancer, obesity, cardiac diseases, neurological disorders, and other chronic diseases. Furthermore, American Red Cross undertakes various initiatives for increasing awareness regarding the importance of blood donation. Blood donation systems in North America are based on a mixed system of non-compensated as well as compensated donations. Moreover, the high demand for advanced technologies coupled with the availability of advanced healthcare infrastructure will augment the regional growth during the forecast period. Maximize Market Research has comprehensively analyzed Platelet, Plasma Market emphasizing on each segment keeping global and regional dynamics in perspective. The driving forces, as well as considerable restraints, have been explained in depth to attain a balanced scenario. The report classifies Platelet, Plasma Market into various segments such as Component, Distribution Channel, Applications, and Regions providing a thorough understanding of the Platelet and Plasma Ecosystem. Importantly, the report delivers forecasts of the market, giving an insight into the future opportunities that exist in the Platelet, Plasma Market. The objective of the report is to present comprehensive Platelet, Plasma Market  including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Platelet, Plasma Market  North America for Asia Pacific dynamics, structure by analyzing the market segments, and project the Platelet, Plasma Market  North America for Asia Pacific   size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Platelet, Plasma Market  North America for Asia Pacific make the report investor’s guide.

The scope of the Platelet, Plasma Market Report:

Platelet, Plasma Market By Component:

Platelet Plasma

Platelet, Plasma Market By Distribution Channel:

Hospitals Ambulatory Surgical Centres Others

Platelet, Plasma Market By Applications:

Haemophilia Thrombocytopenia Perioperative Indications Platelet Function Disorders Coagulation Factor Deficiencies Thrombotic Thrombocytopenic Purpura Haemorrhage Liver Disease

Platelet, Plasma Market By Geography:

North America Europe Asia Pacific Middle East &amp Africa and Latin America

Platelet, Plasma Market -Key Players:

America’s Blood Centres American Red Cross Blood Centres of America European Blood Alliance Indian Red Cross Society Japanese Red Cross Society Red Cross Society of China Spanish Red Cross Saudi Red Crescent Authority South Africa Red Cross Society. AdiStem Ltd. Arthrex, Inc. Biomet, Inc. Cesca Therapeutics, Inc. DePuy Synthes, Inc. EmCyte Corporation Exactech, Inc. Harvest Technologies Corp. Nuo Therapeutics, Inc. Regen Lab SA Stryker Corporation T-Biotechnology (T-LAB) Arthrex, Inc. Terumo BCT, Inc. EmCyte Corporation Success Stories: Key Industry Players American Red Cross Blood Centres of America European Blood Alliance Indian Red Cross Society Japanese Red Cross Society Red Cross Society of China Microfluidics Device Market 

Table of Contents

Platelet, Plasma Market

1. INTRODUCTION 1.1 Report Description 1.1.1 Objectives of the Study 1.1.2 Market Scope 1.1.3 Years considered in the study 1.1.4 Currency 1.1.5 Stakeholders 1.2 Target Audience 1.3 Key Takeaways 2. RESEARCH METHODOLOGY 2.1 Research Methodology 2.2 Market Definition 2.3 Assumptions and Acronyms Used 2.4 Data Sources 2.4.1 Secondary 2.4.1.1 Paid 2.4.1.2 Unpaid 2.4.2 Primary 2.5 Analyst tools and models 3. EXECUTIVE SUMMARY 3.1 Global Platelet and Plasma Market Overview 3.1.1 By Component 3.1.2 By Application 3.1.3 By Distribution Channel 3.1.4 By Geography 4. GLOBAL PLATELET AND PLASMA MARKET OUTLOOK 4.1 Market Definition, Segmentation and Scope of Study 4.2 Market Dynamics 4.2.1 Drivers 4.2.1.1 Rising incidence of haemophilia, thrombocytopenia, autoimmune diseases 4.2.1.2 Increasing blood transfusion rates 4.2.2 Restraints 4.2.2.1 Difficulty in quality control of test results 4.2.3 Opportunities 4.2.3.1 Growth in geriatric population 4.2.3.2 Increase in incidence of sports and orthopaedic injuries 4.3 Market Share Analysis 4.3.1 By Component 4.3.2 By Application 4.3.3 By Distribution Channel 4.3.4 By Geography 4.4 Competitive Analysis 4.4.1 Key Strategic Initiatives 4.4.2 Regional Presence 4.4.3 Product Overview 4.5 Porter’s Analysis 4.6 PESTEL Analysis 4.7 Product Benchmark Analysis 4.8 Company Market Share Analysis 4.9 Key Findings 4.9.1 Top Wining Strategies 4.9.2 Top Investment Pockets 4.9.3 Top Impacting Factors 5. GLOBAL PLATELET AND PLASMA MARKET, BY COMPONENT 5.1 Component Type Segment Analysis & Market Share 5.2 Platelets 5.2.1 Overview 5.2.2 Market Size and Forecast 2019-2026 5.3 Plasma 5.3.1 Overview 5.3.2 Market Size and Forecast 2019-2026 6. GLOBAL PLATELET AND PLASMA MARKET, BY APPLICATION 6.1 Application Type Segment Analysis & Market Share 6.2 Haemophilia 6.2.1 Overview 6.2.2 Market Size and Forecast 2019-2026 6.3 Thrombocytopenia 6.3.1 Overview 6.3.2 Market Size and Forecast 2019-2026 6.4 Perioperative Indications 6.4.1 Overview 6.4.2 Market Size and Forecast 2019-2026 6.5 Platelet Function Disorders 6.5.1 Overview 6.5.2 Market Size and Forecast 2019-2026 6.6 Coagulation Factor Deficiencies 6.6.1 Overview 6.6.2 Market Size and Forecast 2019-2026 6.7 Thrombotic Thrombocytopenic Purpura 6.7.1 Overview 6.7.2 Market Size and Forecast 2019-2026 6.8 Haemorrhage 6.8.1 Overview 6.8.2 Market Size and Forecast 2019-2026 6.9 Liver Disease 6.9.1 Overview 6.9.2 Market Size and Forecast 2019-2026 7. GLOBAL PLATELET AND PLASMA MARKET, BY DISTRIBUTION CHANNEL 7.1 Application Type Segment Analysis & Market Share 7.2 Hospitals 7.2.1 Overview 7.2.2 Market Size and Forecast 2019-2026 7.3 Ambulatory Surgical Centres 7.3.1 Overview 7.3.2 Market Size and Forecast 2019-2026 7.4 Others 7.4.1 Overview 7.4.2 Market Size and Forecast 2019-2026 8. GLOBAL PLATELET AND PLASMA MARKET, BY GEOGRAPHY 9.1 Geography Type Segment Analysis & Market Share 8.1 North America 8.1.1 Overview 8.1.2 Global Standing in Platelet and Plasma Market By Application 8.1.2.1 Haemophilia 8.1.2.2 Thrombocytopenia 8.1.2.3 Perioperative Indications 8.1.2.4 Platelet Function Disorders 8.1.2.5 Coagulation Factor Deficiencies 8.1.2.6 Thrombotic Thrombocytopenic Purpura 8.1.2.7 Haemorrhage 8.1.2.8 Liver Disease 8.1.3 Market Size and Forecast 2019-2026 8.2 Europe 8.2.1 Overview 8.2.2 Global Standing in Platelet and Plasma Market By Application 8.2.2.1 Haemophilia 8.2.2.2 Thrombocytopenia 8.2.2.3 Perioperative Indications 8.2.2.4 Platelet Function Disorders 8.2.2.5 Coagulation Factor Deficiencies 8.2.2.6 Thrombotic Thrombocytopenic Purpura 8.2.2.7 Haemorrhage 8.2.2.8 Liver Disease 8.2.3 Market Size and Forecast 2019-2026 8.3 Asia Pacific 8.3.1 Overview 8.3.2 Global Standing in Platelet and Plasma Market By Application 8.3.2.1 Haemophilia 8.3.2.2 Thrombocytopenia 8.3.2.3 Perioperative Indications 8.3.2.4 Platelet Function Disorders 8.3.2.5 Coagulation Factor Deficiencies 8.3.2.6 Thrombotic Thrombocytopenic Purpura 8.3.2.7 Haemorrhage 8.3.2.8 Liver Disease 8.3.3 Market Size and Forecast 2019-2026 8.4 Latin America, Middle East and Africa 8.4.1 Overview 8.4.2 Global Standing in Platelet and Plasma Market By Application 8.4.2.1 Haemophilia 8.4.2.2 Thrombocytopenia 8.4.2.3 Perioperative Indications 8.4.2.4 Platelet Function Disorders 8.4.2.5 Coagulation Factor Deficiencies 8.4.2.6 Thrombotic Thrombocytopenic Purpura 8.4.2.7 Haemorrhage 8.4.2.8 Liver Disease 8.4.3 Market Size and Forecast 2019-2026 9. COMPITITIVE LANDSCAPE 9.1 Market Share/ Positioning Analysis 9.2 Key Innovators 9.3 Company Profiles 9.3.1 America’s Blood Centres 9.3.1.1 Overview 9.3.1.2 Service Portfolio 9.3.1.3 Global Geographical Footprint 9.3.1.4 Strategic Initiatives 9.3.1.5 SWOT Analysis 9.3.1.6 Competitive Assessment 9.3.2 American Red Cross 9.3.2.1 Overview 9.3.2.2 Service Portfolio 9.3.2.3 Global Geographical Footprint 9.3.2.4 Strategic Initiatives 9.3.2.5 SWOT Analysis 9.3.2.6 Competitive Assessment 9.3.3 Blood Centres of America 9.3.3.1 Overview 9.3.3.2 Service Portfolio 9.3.3.3 Global Geographical Footprint 9.3.3.4 Strategic Initiatives 9.3.3.5 SWOT Analysis 9.3.3.6 Competitive Assessment 9.3.4 European Blood Alliance 9.3.4.1 Overview 9.3.4.2 Service Portfolio 9.3.4.3 Global Geographical Footprint 9.3.4.4 Strategic Initiatives 9.3.4.5 SWOT Analysis 9.3.4.6 Competitive Assessment 9.3.5 Indian Red Cross Society 9.3.5.1 Overview 9.3.5.2 Service Portfolio 9.3.5.3 Global Geographical Footprint 9.3.5.4 Strategic Initiatives 9.3.5.5 SWOT Analysis 9.3.5.6 Competitive Assessment 9.3.6 Japanese Red Cross Society 9.3.6.1 Overview 9.3.6.2 Service Portfolio 9.3.6.3 Global Geographical Footprint 9.3.6.4 Strategic Initiatives 9.3.6.5 SWOT Analysis 9.3.6.6 Competitive Assessment 9.3.7 Red Cross Society of China 9.3.7.1 Overview 9.3.7.2 Service Portfolio 9.3.7.3 Global Geographical Footprint 9.3.7.4 Strategic Initiatives 9.3.7.5 SWOT Analysis 9.3.7.6 Competitive Assessment 9.3.8 Spanish Red Cross 9.3.8.1 Overview 9.3.8.2 Service Portfolio 9.3.8.3 Global Geographical Footprint 9.3.8.4 Strategic Initiatives 9.3.8.5 SWOT Analysis 9.3.8.6 Competitive Assessment 9.3.9 Saudi Red Crescent Authority 9.3.9.1 Overview 9.3.9.2 Service Portfolio 9.3.9.3 Global Geographical Footprint 9.3.9.4 Strategic Initiatives 9.3.9.5 SWOT Analysis 9.3.9.6 Competitive Assessment 9.3.10 South Africa Red Cross Society. 9.3.10.1 Overview 9.3.10.2 Service Portfolio 9.3.10.3 Global Geographical Footprint 9.3.10.4 Strategic Initiatives 9.3.10.5 SWOT Analysis 9.3.10.6 Competitive Assessment 9.3.11 AdiStem Ltd. 9.3.11.1 Overview 9.3.11.2 Service Portfolio 9.3.11.3 Global Geographical Footprint 9.3.11.4 Strategic Initiatives 9.3.11.5 SWOT Analysis 9.3.11.6 Competitive Assessment 9.3.12 Arthrex, Inc. 9.3.12.1 Overview 9.3.12.2 Service Portfolio 9.3.12.3 Global Geographical Footprint 9.3.12.4 Strategic Initiatives 9.3.12.5 SWOT Analysis 9.3.12.6 Competitive Assessment 9.3.13 Biomet, Inc. 9.3.13.1 Overview 9.3.13.2 Service Portfolio 9.3.13.3 Global Geographical Footprint 9.3.13.4 Strategic Initiatives 9.3.13.5 SWOT Analysis 9.3.13.6 Competitive Assessment 9.3.14 Cesca Therapeutics, Inc. 9.3.14.1 Overview 9.3.14.2 Service Portfolio 9.3.14.3 Global Geographical Footprint 9.3.14.4 Strategic Initiatives 9.3.14.5 SWOT Analysis 9.3.14.6 Competitive Assessment 9.3.15 DePuy Synthes, Inc. 9.3.15.1 Overview 9.3.15.2 Service Portfolio 9.3.15.3 Global Geographical Footprint 9.3.15.4 Strategic Initiatives 9.3.15.5 SWOT Analysis 9.3.15.6 Competitive Assessment 9.3.16 EmCyte Corporation 9.3.16.1 Overview 9.3.16.2 Service Portfolio 9.3.16.3 Global Geographical Footprint 9.3.16.4 Strategic Initiatives 9.3.16.5 SWOT Analysis 9.3.16.6 Competitive Assessment 9.3.17 Exactech, Inc. 9.3.17.1 Overview 9.3.17.2 Service Portfolio 9.3.17.3 Global Geographical Footprint 9.3.17.4 Strategic Initiatives 9.3.17.5 SWOT Analysis 9.3.17.6 Competitive Assessment 9.3.18 Harvest Technologies Corp. 9.3.18.1 Overview 9.3.18.2 Service Portfolio 9.3.18.3 Global Geographical Footprint 9.3.18.4 Strategic Initiatives 9.3.18.5 SWOT Analysis 9.3.18.6 Competitive Assessment 9.3.19 Nuo Therapeutics, Inc. 9.3.19.1 Overview 9.3.19.2 Service Portfolio 9.3.19.3 Global Geographical Footprint 9.3.19.4 Strategic Initiatives 9.3.19.5 SWOT Analysis 9.3.19.6 Competitive Assessment 9.3.20 Regen Lab SA 9.3.20.1 Overview 9.3.20.2 Service Portfolio 9.3.20.3 Global Geographical Footprint 9.3.20.4 Strategic Initiatives 9.3.20.5 SWOT Analysis 9.3.20.6 Competitive Assessment 9.3.21 Stryker Corporation 9.3.21.1 Overview 9.3.21.2 Service Portfolio 9.3.21.3 Global Geographical Footprint 9.3.21.4 Strategic Initiatives 9.3.21.5 SWOT Analysis 9.3.21.6 Competitive Assessment 9.3.22 T-Biotechnology (T-LAB) 9.3.22.1 Overview 9.3.22.2 Service Portfolio 9.3.22.3 Global Geographical Footprint 9.3.22.4 Strategic Initiatives 9.3.22.5 SWOT Analysis 9.3.22.6 Competitive Assessment 9.3.23 Arthrex, Inc. 9.3.23.1 Overview 9.3.23.2 Service Portfolio 9.3.23.3 Global Geographical Footprint 9.3.23.4 Strategic Initiatives 9.3.23.5 SWOT Analysis 9.3.23.6 Competitive Assessment 9.3.24 Terumo BCT, Inc. 9.3.24.1 Overview 9.3.24.2 Service Portfolio 9.3.24.3 Global Geographical Footprint 9.3.24.4 Strategic Initiatives 9.3.24.5 SWOT Analysis 9.3.24.6 Competitive Assessment 9.3.25 EmCyte Corporation 9.3.25.1 Overview 9.3.25.2 Service Portfolio 9.3.25.3 Global Geographical Footprint 9.3.25.4 Strategic Initiatives 9.3.25.5 SWOT Analysis 9.3.25.6 Competitive Assessment 9.4 Global Platelet and Plasma Market – Benchmarking 9.4.1 Changing Competitive Landscape 9.4.2 Benchmarking 9.4.2.1 Product Based 9.4.2.2 Revenue Based 9.4.2.3 Service Based 9.4.2.4 One-stop-shop vs. Niche entities 9.4.2.5 Cross-Industrial Applications 10. SUCCESS STORIES: KEY INDUSTRY PLAYERS 10.1 American Red Cross 10.2 Blood Centres of America 10.3 European Blood Alliance 10.4 Indian Red Cross Society 10.5 Japanese Red Cross Society 10.6 Red Cross Society of China 11. CONSOLIDATION 11.1 Mergers and Acquisitions 11.1.1 Overview 11.1.2 Key Drivers – By Region 11.1.3 M&A Breakdown 11.1.3.1 Asset & Non-Asset Based 11.1.3.2 Venture Capitalist Based 11.2 Fragmentation of Global Platelet and Plasma Market 11.3 Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements 11.4 New/Emerging Models of Partnerships 11.5 New/Emerging Business Models 11.5.1 Strategic Analysis of Platelet and Plasma Business Models 11.5.1.1 Platelet and Plasma-as-a-service 11.5.2 Market share analysis of various business models 11.5.3 Emerging Trends – Key Examples 11.6 Changing Investment Paradigm: Focused areas by Key Players 11.7 Patent Analysis 12. LIST OF TABLES 13. LIST OF FIGURES

About This Report

Report ID11293
Category Healthcare
Published Dateoct 2019
No of Pages313
Contact Us
Call Now